Eli Lilly and Company (NYSE:LLY) is Cohen Investment Advisors LLC's Largest Position

Cohen Investment Advisors LLC grew its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 7,975.5% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 783,651 shares of the company's stock after acquiring an additional 773,947 shares during the quarter. Eli Lilly and Company comprises 16.9% of Cohen Investment Advisors LLC's holdings, making the stock its largest position. Cohen Investment Advisors LLC owned 0.08% of Eli Lilly and Company worth $647,225,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. GAMMA Investing LLC raised its holdings in Eli Lilly and Company by 103,831.6% in the 1st quarter. GAMMA Investing LLC now owns 14,866,380 shares of the company's stock valued at $12,278,292,000 after acquiring an additional 14,852,076 shares during the last quarter. Norges Bank purchased a new stake in shares of Eli Lilly and Company in the fourth quarter valued at approximately $8,407,908,000. Wellington Management Group LLP increased its holdings in shares of Eli Lilly and Company by 19.0% in the fourth quarter. Wellington Management Group LLP now owns 12,625,925 shares of the company's stock valued at $9,747,214,000 after purchasing an additional 2,012,129 shares during the last quarter. Capital International Investors increased its holdings in shares of Eli Lilly and Company by 23.2% in the fourth quarter. Capital International Investors now owns 8,730,758 shares of the company's stock valued at $6,740,272,000 after purchasing an additional 1,645,222 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in Eli Lilly and Company during the fourth quarter worth approximately $1,240,653,000. Hedge funds and other institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Up 0.5%

Shares of LLY stock traded up $3.90 on Monday, hitting $779.35. The stock had a trading volume of 3,040,079 shares, compared to its average volume of 3,681,016. The company has a debt-to-equity ratio of 2.18, a current ratio of 1.37 and a quick ratio of 1.06. The firm has a market capitalization of $738.62 billion, a P/E ratio of 63.41, a P/E/G ratio of 1.13 and a beta of 0.41. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company's 50 day moving average price is $780.19 and its 200-day moving average price is $800.08.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share for the quarter, missing the consensus estimate of $4.64 by ($1.30). The firm had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 22.67% and a return on equity of 85.51%. The business's revenue was up 45.2% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.58 earnings per share. Analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Investors of record on Friday, August 15th will be paid a dividend of $1.50 per share. This represents a $6.00 annualized dividend and a yield of 0.77%. The ex-dividend date of this dividend is Friday, August 15th. Eli Lilly and Company's payout ratio is currently 48.82%.

Analysts Set New Price Targets

A number of brokerages have issued reports on LLY. Cantor Fitzgerald began coverage on Eli Lilly and Company in a research note on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 target price for the company. Guggenheim restated a "buy" rating and set a $936.00 price objective on shares of Eli Lilly and Company in a research report on Friday, June 20th. UBS Group reduced their target price on shares of Eli Lilly and Company from $1,100.00 to $1,050.00 and set a "buy" rating on the stock in a research note on Friday, May 2nd. HSBC cut shares of Eli Lilly and Company from a "buy" rating to a "reduce" rating and dropped their price target for the company from $1,150.00 to $700.00 in a research note on Monday, April 28th. Finally, The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and reduced their price target for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and sixteen have assigned a buy rating to the company's stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $1,011.61.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.